Skip to main content
Clinical Trials/NCT02006797
NCT02006797
Unknown
Not Applicable

Impact of Drug Reconciliation at Discharge and Pharmaceutical Communication Between Hospital and Community Pharmacists on Drug Related Problems: Study Protocol for a Cluster Randomized Cross-over Trial

University Hospital, Tours14 sites in 1 country1,176 target enrollmentJanuary 2014
ConditionsTreatment Error

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Treatment Error
Sponsor
University Hospital, Tours
Enrollment
1176
Locations
14
Primary Endpoint
drug related problems (DRP)
Last Updated
12 years ago

Overview

Brief Summary

This study will evaluate the impact of a communication between hospital pharmacist and community pharmacists in addition to drugs reconciliation procedure at discharge. It will be conducted in 21 french public hospitals.

Detailed Description

Transition points during hospitalization are at risk of drug related problems (DRP) especially admission and discharge. Reconciliation procedure at admission lead by a clinical pharmacist had been proved to decrease DRP. The community pharmacist (CP) is often the first health professional that patients meet at discharge. He/she is in charge of dispensing their medication to patients and give treatment information. However because of lack of information community pharmacist is not always able to identify problems and this may lead to dispense wrong drugs and/or wrong dosage and/or give wrong information. The objective of this study is to assess the impact of drug reconciliation performed at discharge completed by a communication between the Hospital Pharmacist (HP) and community pharmacist on drug related problem during the 7 days following discharge at home. The study is a cluster randomized cross-over trial. It involves 21 French universitarian and non-universitarian hospitals with 42 care units: 22 medical units and 20 surgical units. Each unit (a unit corresponds to a cluster) is involved during two consecutive 14-day periods which are randomly assigned as "experimental" or "control" where control corresponds to usual care. During the experimental period, for each eligible patient discharged during the period, a reconciliation procedure will be performed by the HP, with communication to the patient. The HP will further inform the patient's community pharmacist about patient's drug therapy \[modification in home medication, acute drugs prescribed, shelved treatments and/or labs results to survey patient\]. Eligible patients will be over 18, attending to the same community pharmacist for at least 3 months. We will exclude patients with a length stay over 21 days (too many therapeutic modifications), those who do not return to home, and also palliative patient. The primary outcome is a composite outcome associating any kind of drug misuse during the 7 days following discharge. It will be assessed by phone at day 7 (+/-2) by a pharmacist in charge of the study (PCS) will phone both patients and community pharmacists . The secondary outcome will be the unplanned hospitalizations observed in each group assessed by phone at day 35 (+/-5). We plan to recruit 1,176 patients, i.e. 14 per period per unit. This study will assess the impact of a reconciliation procedure at discharge followed by a communication between HP and community pharmacists . Also it will identify the type of patients for which the intervention is the most relevant in France and may be generalized to other countries that have the same care organisation.

Registry
clinicaltrials.gov
Start Date
January 2014
End Date
December 2015
Last Updated
12 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • patients over 18
  • patients attending to the same CP for at least 3 months
  • patients speaking french

Exclusion Criteria

  • patients with a length stay over 21 days (too many therapeutic modifications),
  • patients who do not return to home,
  • palliative patients and/or expected end of life
  • patients that will not give their informed consent

Outcomes

Primary Outcomes

drug related problems (DRP)

Time Frame: 7 days after patient discharge

The primary outcome is a composite endpoint associated all the problems/dysfunctions that can be observed from the hospital to home during 7 days after discharge. We will be taking in account the occurence of a dysfunction every time that one of the following problems will happen: - first drug problem; the drug taken by the patient has a problem: it is not the right medicine (Name, form, route, dose). The fault may be 1) an error between the processing of transcription at the admission and the discharge, 2) a therapeutic modification related to therapeutic formulary restriction, the home medication is replaced by an another one that may be less adaptated to patient, 3) an error linked to the writing. Second : patient due to patient; the patient doesn't take what was prescribed and / or treatments that he takes are stopped. Third- :presence of a gap in the continuity and duration of therapy: the patient could not have his medication when he's coming at the pharmacy

Secondary Outcomes

  • clinical impact of problems(days 7 after discharge)
  • patient satisfaction(day 7 after patient discharge)
  • number of non-planned hospitalization(days 35 after discharge)
  • time spend by hospital pharmacist on reconciliation and communication to community pharmacist(at day 2/3 after discharge)
  • all compounds of the composite primary outcome measure (patient errors, medical error and DRP)(day 7 after discharge)
  • community pharmacist satisfaction about exchanges with hospital pharmacists(7 days after patient discharge)
  • percentage of drugs prescription modified by the hospital pharmacist at discharge(at discharge)

Study Sites (14)

Loading locations...

Similar Trials